Top 10 Infection Control Companies

Why Infection Control Is Expanding?

The Global Infection Control Market reached an estimated USD 44.5 billion in 2024 and is projected to grow to USD 81.05 billion by 2035, expanding at a CAGR of 5.6% over the 2025--2035 forecast period. This trajectory is anchored in a persistent global burden of healthcare-associated infections (HAIs): the Centers for Disease Control and Prevention estimates that 1 in 31 hospital patients acquires at least one HAI daily, contributing to approximately 1.7 million infections and 99,000 deaths annually in the U.S. alone.

The World Health Organization further reports that 7--10% of hospitalized patients globally acquire infections, with rates reaching 15% in developing countries --- a structural demand driver that transcends economic cycles and underpins sustained procurement of disinfection, sterilization, and protective barrier solutions.

The way infection control is applied in both healthcare and non-healthcare settings is changing due to a fundamental shift in technology. Automated disinfection systems, such as UV-C light and hydrogen peroxide vapor technologies, are becoming more popular since CDC research indicates that improved environmental cleaning can cut hospital microorganisms by 30–40%. With 38% of the market, disinfectants are the most popular product category, although pandemic-era awareness has led to a notable increase in Personal Protective Equipment (PPE).

Hospitals account for 42% of all applications, which reflects universal regulatory requirements for surgical sterilization and patient care hygiene. The fastest-growing application area is pharmaceuticals, as the production of biologics and advanced therapies necessitates strict contamination control. With more than 40% of worldwide income, North America leads, followed by Europe with 30% thanks to ECDC regulations.

What Structurally Separates Leaders from the Field?

Four structural factors are identified by MRFR as defining category leadership in the infection control market: integrated product-to-service platform architecture encompassing manufacturing, distribution, and on-site technical support; regulatory validation depth and EPA/FDA registration breadth that translate compliance requirements into recurring procurement contracts; scale-driven cost advantages in consumables production that lock in hospital group purchasing organization (GPO) contracts; and technology investment in automated disinfection, real-time environmental monitoring, and AI-driven compliance analytics.

While distributors with Prime Vendor ties create switching costs that smaller competitors cannot overcome, companies in charge of proprietary disinfection formulations with broad-spectrum pathogen claims require premium pricing and multi-year supply agreements. The addressable market is growing by an estimated 15–20% as a result of the post-pandemic normalization of infection prevention in industries other than healthcare, such as food processing, hotels, and education.

Top 10 Global Infection Control Companies --- MRFR Rankings (2026)

MRFR has identified and profiled the following leading infection control companies globally, evaluated on the basis of revenue performance, geographic presence, product portfolio breadth, regulatory validation depth, GPO contract density, and technology innovation. Figures below have been validated against company filings, investor-relations disclosures, and official company websites as of June 2026.

Detailed Company Profiles

1. Johnson & Johnson (MedTech) | NYSE: JNJ | New Brunswick, New Jersey, USA

According to its SEC Form 10-K filing, Johnson & Johnson's MedTech business contributed roughly USD 31.9 billion to the company's overall group revenue of USD 88.82 billion in FY2024. Advanced sterilization monitoring systems, antimicrobial surgical drapes, and Ethicon surgical sutures and wound closure products—the world leader in surgical infection prevention—are the cornerstones of the company's infection control portfolio.

J&J's integrated pharma-medtech model, which creates antimicrobial-coated surgical implants and the infection prevention guidelines that direct their use, is its strategic moat. It captures value throughout the surgical care continuum, from pre-operative skin preparation to post-operative wound management. With more than 500,000 healthcare workers trained in aseptic technique and surgical site infection prevention each year, the company's 138,100 employees and presence in more than 100 countries offer an unparalleled clinical education infrastructure.

2. 3M Company | NYSE: MMM | Saint Paul, Minnesota, USA

According to its SEC Form 10-K filing, 3M Company reported total sales of USD 24.58 billion in FY2024. In April 2024, the corporation successfully spun out its Health Care division as Solventum, keeping a 19.9% ownership share worth USD 2.3 billion. The Safety & Industrial, Transportation & Electronics, and Consumer sectors comprise 3M's remaining portfolio following the spin-off.

Solventum acquired the company's previous infection control portfolio, which included N95 respirators, surgical drapes and gowns, sterilization assurance products, and skin preparation solutions. Historically, 3M's strategic distinction has been rooted in its materials science history. Product-level moats were built by superior adhesive systems in surgical drapes and proprietary filter media technology in N95 respirators.

3. Ecolab | NYSE: ECL | Saint Paul, Minnesota, USA

Ecolab reported total revenue of USD 15.74 billion in FY2024, per its SEC Form 10-K filing, with its Global Institutional & Specialty segment contributing approximately USD 5.41 billion. The company's healthcare division offers end-to-end infection prevention programs combining disinfectant formulations, dispensing systems, compliance monitoring, and on-site technical service --- a bundled model that converts product sales into multi-year service contracts.

Ecolab's strategic moat is built on its water-chemistry expertise: the company's proprietary quaternary ammonium and peracetic acid formulations are EPA-registered against the broadest pathogen spectrum in the industry, including C. difficile spores and emerging viral threats. With operations in 170+ countries and 47,000 employees, Ecolab provides the only truly global infection prevention service infrastructure, enabling multinational hospital chains to standardize protocols across facilities regardless of geography.

4. Becton, Dickinson and Company (BD) | NYSE: BD | Franklin Lakes, New Jersey, USA

According to its SEC Form 10-K filing, Becton, Dickinson and Company recorded total sales of USD 20.17 billion in FY2024, with its BD Medical division contributing about USD 9.5 billion. Needlestick injuries and the spread of bloodborne pathogens in clinical settings are prevented by the BD Vacutainer blood collection system, safety-engineered syringes, and sharps disposal solutions, which form the foundation of BD's infection control portfolio.

The company's regulatory depth is what sets it apart strategically: BD has more FDA 510(k) certifications for safety-engineered devices than any rival, and its products are included as exemplar engineering controls in OSHA bloodborne pathogen regulations. With direct connections to 95% of U.S. hospitals and a presence in more than 190 countries, BD has a distribution density that facilitates the quick implementation of novel infection prevention technology during outbreak reactions.

5. Medline Industries (Medline Inc.) | Nasdaq: MDLN | Northfield, Illinois, USA

Medline reported net sales of USD 25.5 billion in FY2024, accelerating to USD 28.4 billion in FY2025 following its December 2025 IPO on Nasdaq, per its SEC S-1 and subsequent 10-K filings. The company is the largest provider of medical-surgical products and supply chain solutions in the United States, operating in 125+ countries with 45,000+ employees and offering 550,000+ SKUs. Medline's infection control portfolio spans PPE, sterilization products, disinfectants, and surgical supplies --- distributed through a vertically integrated model where the Medline Brand segment (48.7% of revenue) generates 81.8% of segment EBITDA through proprietary manufacturing.

The company's Prime Vendor relationships with major health systems like Johns Hopkins and Northwestern Medicine create multi-year exclusive supply agreements that embed Medline as the primary infection control vendor across the entire continuum of care. In 2024, Medline completed its USD 950 million acquisition of Ecolab's surgical solutions business, adding operating room equipment, Microtek sterile drapes, and fluid temperature management systems to its portfolio.

6. Steris Corporation | NYSE: STE | Mentor, Ohio, USA

According to its SEC Form 10-K filing, Steris Corporation recorded total sales of USD 5.46 billion in FY2024, with its healthcare business contributing roughly USD 3.61 billion. The company, which specializes in low-temperature hydrogen peroxide vapor and ethylene oxide sterilization systems for temperature-sensitive medical devices, is the world leader in sterilization equipment and contract sterilization services.

Steris's installed base of more than 15,000 sterilization systems worldwide—a capital equipment footprint that generates high-margin consumables and service revenue for decades after original installation—is its strategic moat. The company has expanded its infection prevention portfolio into endoscope reprocessing, water purification, and dental infection control through its acquisition-driven growth strategy, which includes the USD 4.6 billion acquisition of Cantel Medical in 2021.

7. Cardinal Health | NYSE: CAH | Dublin, Ohio, USA

Cardinal Health reported total revenue of USD 226.9 billion in FY2024, per its SEC Form 10-K filing, with its Global Medical Products and Distribution segment contributing approximately USD 12.4 billion. The company's infection control portfolio is distributed through its medical segment, encompassing surgical and infection prevention products, PPE, and sterilization supplies sold to hospitals, ambulatory surgery centers, and physician offices.

Cardinal's strategic position is anchored in its scale as the second-largest medical distributor in the United States, with GPO contracts covering over 75% of U.S. hospitals --- a distribution density that ensures Cardinal-branded infection control products are specified in procurement catalogs regardless of brand preference. The company's 2024 segment profit margin of 0.74% in Global Medical Products reflects the thin-margin, high-volume nature of distribution, but its 11% revenue growth in Pharmaceutical and Specialty Solutions provides cross-subsidy capacity for medical segment expansion.

8. Owens & Minor (HALYARD) | NYSE: OMI | Richmond, Virginia, USA

According to its SEC Form 10-K filing, Owens & Minor recorded total revenue of USD 10.7 billion in FY2024, with its Products & Healthcare Services business contributing about USD 8.0 billion. Sterilization wraps, surgical drapes, and personal protective equipment (PPE) are all part of the corporation's HALYARD brand, which was acquired from the former Halyard Health company and is currently run under the Owens & Minor umbrella.

In order to make a strategy shift toward its higher-growth, higher-margin Patient Direct division (home medical equipment and diabetes supplies), Owens & Minor revealed in 2025 that it was actively discussing the possible sale of its Products & Healthcare Services segment. Surgical disposables and sterilizing products marketed through its medical distribution division account for the majority of the company's infection control revenue; the combined business's FY2024 adjusted EBITDA was USD 523 million.

9. Diversey Holdings | Private (Solenis) | Fort Mill, South Carolina, USA

Diversey Holdings reported total revenue of approximately USD 3.28 billion in FY2024, per SEC filings prior to its acquisition by Solenis in 2023. The company's infection control portfolio focuses on healthcare environmental hygiene --- including disinfectants, cleaning chemicals, and floor care products --- with a sustainability positioning that differentiates it from commodity chemical competitors.

Diversey's strategic niche lies in its LEED-certified formulations and closed-loop dispensing systems that reduce chemical waste and water consumption --- a value proposition that resonates with healthcare systems pursuing environmental sustainability certifications. The company's 80+ country footprint and focus on the healthcare and hospitality sectors provide cross-selling opportunities as hotels and hospitals adopt unified hygiene standards post-pandemic.

10. Getinge | OMX: GETI B | Gothenburg, Sweden

Getinge reported total revenue of SEK 30.8 billion (~USD 2.9 billion) in FY2024, per its Annual Report, with its Infection Control business area contributing approximately SEK 12.5 billion. The company is the European leader in sterilization systems, automated washer-disinfectors, and central sterile supply department (CSSD) workflow solutions --- a specialized focus that makes Getinge the default supplier for hospital sterilization infrastructure in Europe and increasingly in Asia-Pacific.

Getinge's strategic differentiation lies in its acute care technology integration: its sterilization systems communicate with hospital information systems to track instrument utilization, maintenance schedules, and compliance metrics --- a connectivity layer that competitors selling standalone equipment cannot match. The company's 135+ country presence and direct sales force specializing in CSSD workflow optimization provide consultative selling capabilities that differentiate Getinge from distributors offering commoditized sterilization products.

M&A Activity Tracker (2021--2025)

The Infection Control Market has experienced targeted consolidation as platform companies pursued inorganic growth to capture the converging disinfection, sterilization, and PPE segments. Market Research Future tracks the following verified, named transactions directly relevant to the infection control market.

Key Trend: MRFR analysis identifies vertical integration of manufacturing with distribution as the dominant competitive dynamic in infection control. Medline's USD 950 million acquisition of Ecolab's surgical solutions and its 81.8% EBITDA concentration in owned brands demonstrate that distributors with proprietary manufacturing capture disproportionate margin. Conversely, Owens & Minor's exploration of divesting its Products & Healthcare Services segment signals that pure distribution without manufacturing differentiation is structurally challenged. By 2030, MRFR projects that platform operators combining disinfectant formulation, sterilization equipment, and digital compliance monitoring under one vendor relationship will capture 45--50% of hospital infection control spending, up from under 30% today.

R&D Investment & Innovation Signals

• Johnson & Johnson's MedTech segment continues to invest in antimicrobial-coated surgical implants and advanced wound closure technologies, with Ethicon maintaining its position as the global #1 surgical suture brand --- a market leadership that generates recurring demand for complementary infection prevention products across the surgical care continuum.

• 3M completed the Solventum spin-off in April 2024, transferring its healthcare business (including N95 respirators and surgical drapes) to the newly independent company while retaining a 19.9% stake --- a structural repositioning that removes 3M from direct infection control competition while providing continued healthcare market exposure.

• Ecolab's service-contract model generates 60%+ recurring revenue through on-site technical support and compliance monitoring --- a 'sticky' operational integration that competitors selling commodity disinfectants cannot displace without offering equivalent field service infrastructure.

• Medline completed its USD 950 million acquisition of Ecolab's surgical solutions business in 2024, adding Microtek sterile drapes and OR equipment to its portfolio, and subsequently completed a USD 6.26 billion IPO in December 2025 --- the largest healthcare IPO of the year --- providing capital to fund continued infection control technology acquisitions.

• Steris Corporation's installed base of 15,000+ sterilization systems worldwide generates high-margin consumables and service revenue for decades post-installation --- a capital equipment annuity that competitors without equivalent scale cannot replicate.